Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022
Blood-based multimodal test achieved 100% sensitivity for colorectal cancer at 90% specificity in a prospective study of 557 individuals PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision ...